INVESTIGATION ALERT: Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and Encourages Long-Term Investors to Contact the Firm

INVESTIGATION ALERT: Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and Encourages Long-Term Investors to Contact the Firm

PR Newswire

PHILADELPHIA, Jan. 8, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal") on behalf of the Company's shareholders.

Since March 2019, shares of Amneal's common stock have declined in value from over $14.00 per share to a current trading price of below $6.00 per share, a cumulative decline of over 57% in value.

The investigation seeks to determine whether Amneal and/or the company's representatives violated the securities laws by issuing false and/or misleading statements and failing to disclose material information to the company's investors.

Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by email ([email protected] / [email protected]) or online at https://kaskelalaw.com/cases/amneal-pharmaceuticals/ , for additional information about this investigation and their legal rights and options.

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. This notice may constitute attorney advertising in certain jurisdictions.

CONTACT:

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com

Cision View original content:https://www.prnewswire.com/news-releases/investigation-alert-kaskela-law-llc-announces-investigation-of-amneal-pharmaceuticals-inc-nyse-amrx-and-encourages-long-term-investors-to-contact-the-firm-302028147.html

SOURCE Kaskela Law LLC

Copyright CNW Group 2024